Blaine Davis - Nov 13, 2023 Form 4 Insider Report for Cartesian Therapeutics, Inc. (SELB)

Role: Chief Financial Officer
Signature: Matthew Bartholomae, Attorney-in-Fact for Blaine Davis
Stock symbol: SELB
Transactions as of: Nov 13, 2023
Transactions value $: -$987,500
Form type: 4
Date filed: 11/15/2023, 05:26 PM
Previous filing: Nov 30, 2022
Next filing: Jan 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SELB	Employee Stock Option (right to buy)	Disposed to Issuer	-$988K	-1.25M	-100%	$0.79	0	Nov 13, 2023	Common Stock	1.25M	$1.27	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.

Content

This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.